
Celgene appoints new UK general manager
pharmafile | December 9, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Celgene, Wim Souverijns
Celgene has appointed Wim Souverijns as its new vice president and general manager for UK and Ireland.
Souverijns (pictured) takes over from Samantha Pearce who has moved across to fulfil the role in its EMEA emerging markets unit.
Souverijns has worked in the pharma industry for almost 15 years, and joined Celgene in 2007 as head of the European marketing operations team.
In 2009, he then relocated to the US to establish the firm’s global marketing excellence function and was later promoted to executive director. He returned to Europe in 2012 to take up the position of general manager for the Nordic countries.
Commenting on his role Souverijns says: “I have had the privilege of working for Celgene for a number of years and I am eager to continue our commitment here in the UK and Ireland to patients with cancer, inflammatory and immune-related diseases.”
Marie-France Tschudin, who is the corporate VP and head of its haematology and oncology EMEA unit, adds: “We are delighted that Wim has accepted the position of general manager for the UK & Ireland organisation.”
Related Content

NICE recommends Celgene’s REVLIMID for multiple myeloma
NICE has issued a Final Appraisal Document (FAD) recommending Celgene’s REVLIMID (lenalidomide) as maintenance treatment …

NICE opts to reject Celgene’s Revlimid for newly diagnosed multiple myeloma after an autologous stem cell transplant
It has emerged that NICE has opted to reject Celgene’s Revlimid (lenalidomide) for the maintenance …

NICE recommends Celgene’s Revlimid combo for follicular lymphoma
NICE has chosen to recommend Celgene’s Revlimid (lenalidomide) for use on the NHS, it has …






